How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,013 results for

Topical Ointment

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Safety and Efficacy of Diacerein 1% Ointment Topical Formulation Compared to Placebo for Subjects With Epidermolysis Bullosa Simplex (EBS)

Safety and Efficacy of Diacerein 1% Ointment Topical Formulation Compared to Placebo for Subjects With Epidermolysis Bullosa Simplex (EBS) Safety and Efficacy of Diacerein 1% Ointment Topical Formulation Compared to Placebo for Subjects With Epidermolysis Bullosa Simplex (EBS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy of Diacerein 1% Ointment Topical Formulation Compared to Placebo for Subjects With Epidermolysis Bullosa Simplex (EBS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov

2017 Clinical Trials

22. Study of Topical SOR007 Ointment for Cutaneous Metastases

Study of Topical SOR007 Ointment for Cutaneous Metastases Study of Topical SOR007 Ointment for Cutaneous Metastases - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study of Topical SOR007 Ointment (...) Biotest, Inc. Information provided by (Responsible Party): NanOlogy, LLC Study Details Study Description Go to Brief Summary: This study evaluates a topical nanoparticle paclitaxel ointment (SOR007) for the treatment of cutaneous metastases from non-melanoma cancer in adults. Three concentrations of SOR007 will be evaluated in dose-rising cohorts of three. An expanded cohort will treat additional subjects at the maximum tolerated dose. Condition or disease Intervention/treatment Phase Cutaneous

2017 Clinical Trials

23. Comparative Efficacy of Topical Pertmehrin, Crotamiton and Sulfur Ointment in Treatment of Scabies (PubMed)

Comparative Efficacy of Topical Pertmehrin, Crotamiton and Sulfur Ointment in Treatment of Scabies Scabies is an ectoparasitic infection, which occurs because of direct skin-to skin contact. The ideal treatment modality is still unclear and further research on this topic is warranted. The aim of the study was to compare the efficacy and safety of the topical scabicides: permethrin, crotamiton and sulfur ointment.Fifty four patients with diagnosed scabies were randomly divided into three (...) treatment groups. The first group received 5% permethrin cream twice with one week interval, the patients from the second group were given crotamiton lotion for two days twice with one week interval, while the third group received 10% sulfur ointment for two or three weeks. All patients were followed up at 1, 2 and 4 weeks intervals.At one-week follow up the cure rate was significantly higher at permethrin-treated group when compared to crotamiton group (P< 0.001) and sulfur group (P< 0.001). At the end

Full Text available with Trip Pro

2017 Journal of Arthropod-Borne Diseases

24. Successful Management of Zoon’s Balanitis with Topical Mupirocin Ointment: A Case Report and Literature Review of Mupirocin-Responsive Balanitis Circumscripta Plasmacelluaris (PubMed)

Successful Management of Zoon’s Balanitis with Topical Mupirocin Ointment: A Case Report and Literature Review of Mupirocin-Responsive Balanitis Circumscripta Plasmacelluaris Zoon's balanitis, also referred to as balanitis circumscripta plasmacellularis (BCP), is an idiopathic, benign inflammatory condition of the glans penis and foreskin most often seen in elderly uncircumcised men. A patient with a biopsy-confirmed diagnosis of BCP who was successfully treated with topical mupirocin (...) ointment is described.The PubMed database was searched with the key words: bactroban, balanitis, cell, circumscripta, mupirocin, plasma, plasmacellularis, tacrolimus, Zoon. The papers generated by the search and their references were reviewed.Treatments for BCP have previously included circumcision and topical calcineurin inhibitors. Our patient with BCP rapidly resolved after initiating treatment with mupirocin 2% ointment.BCP is a benign dermatosis affecting the glans penis and foreskin. We confirm

Full Text available with Trip Pro

2017 Dermatology and therapy

25. Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma: A Randomized Clinical Trial (PubMed)

Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma: A Randomized Clinical Trial 28793140 2019 01 28 2019 01 28 2168-6084 153 10 2017 10 01 JAMA dermatology JAMA Dermatol Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma: A Randomized Clinical Trial. 1061-1063 10.1001/jamadermatol.2017.2529 Kessels Janneke J Department of Dermatology, Maastricht University Medical Center, Maastricht, the Netherlands. GROW School for Developmental Biology (...) . Kelleners-Smeets Nicole W J NWJ Department of Dermatology, Maastricht University Medical Center, Maastricht, the Netherlands. GROW School for Developmental Biology and Oncology, Maastricht University, Maastricht, the Netherlands. eng Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't United States JAMA Dermatol 101589530 2168-6068 0 Ointments 0 green tea extract polyphenone E 8R1V1STN48 Catechin AIM IM Administration, Topical Biopsy Camellia sinensis Carcinoma, Basal Cell

Full Text available with Trip Pro

2017 JAMA dermatology

26. A Novel Topical Combination Ointment with Antimicrobial Activity against Methicillin-Resistant Staphylococcus aureus, Gram-Negative Superbugs, Yeasts, and Dermatophytic Fungi (PubMed)

A Novel Topical Combination Ointment with Antimicrobial Activity against Methicillin-Resistant Staphylococcus aureus, Gram-Negative Superbugs, Yeasts, and Dermatophytic Fungi The use of topical antimicrobial agents for management of minor skin infections is a clinical strategy that is commonly practiced in the community. Coupled with the use of topical antimicrobial agents is the emergence of antibiotic-resistant strains of pathogens leading to the need for alternative treatments.A novel (...) topical combination ointment consisting of salicylic acid, oak bark extract, benzoic acid, and polyethylene glycol (Bensal HP, Sonar products Inc., Carlstadt, NJ) with antimicrobial properties was assessed to determine its spectrum of activity.One hundred eighty-four bacterial and fungal isolates from culture collections that included multidrug-resistant bacteria such as methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter spp, and gram-negative so-called superbugs

Full Text available with Trip Pro

2016 Current therapeutic research, clinical and experimental

27. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study (PubMed)

Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study Phosphodiesterase-4 (PDE4) is a promising target in atopic dermatitis (AD) treatment. The pharmacokinetics (PK), safety, and efficacy of crisaborole topical ointment, 2% (formerly AN2728) (Anacor Pharmaceuticals, Palo Alto, CA), a boron-based benzoxaborole PDE4 inhibitor, were evaluated in children with mild to moderate AD.This phase 1b, open (...) -label, maximal-use study of crisaborole topical ointment, 2% applied twice daily (dose 3 mg/cm(2) ) for 28 days enrolled patients ages 2 to 17 years with extensive AD involving 25% or more or 35% or more treatable body surface area, depending on age. Primary PK and safety assessments included systemic exposure to crisaborole and its metabolites after 7 days of treatment and the incidence of treatment-emergent adverse events (TEAEs). Secondary efficacy assessments included change from baseline

Full Text available with Trip Pro

2016 Pediatric dermatology

28. A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque

A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age (...) Psoriasis Drug: pefcalcitol ointment, 0.005% Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 50 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks

2016 Clinical Trials

29. Vitamin D Levels Following Topical Application of Vitamin D Ointment

Vitamin D Levels Following Topical Application of Vitamin D Ointment Vitamin D Levels Following Topical Application of Vitamin D Ointment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Vitamin D Levels (...) Following Topical Application of Vitamin D Ointment (VITD-001) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02676674 Recruitment Status : Completed First Posted : February 8, 2016 Last Update Posted : July 21, 2017 Sponsor: University of Minnesota - Clinical and Translational Science Institute

2016 Clinical Trials

30. Topical Ointment

Topical Ointment Topical Ointment Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Topical Ointment Topical Ointment Aka: Topical (...) ) May occlude s more than less occlusive (such as s) VI. Pharmacology ointments are more potent than creams Ointment vehicle holds steroid to skin surface Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Topical Ointment." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Pharmacology About FPnotebook.com is a rapid access, point-of-care

2018 FP Notebook

31. Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis

Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02945657 Recruitment Status : Completed First Posted : October 26, 2016 Results First Posted : November 19, 2018

2016 Clinical Trials

32. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. (PubMed)

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. Additional topical treatments for atopic dermatitis (AD) are needed that provide relief while minimizing risks.We sought to assess the efficacy and safety of crisaborole ointment, a phosphodiesterase 4 inhibitor, in two phase III AD studies (AD-301: NCT02118766; AD-302: NCT02118792).Two identically designed, vehicle

Full Text available with Trip Pro

2016 Journal of American Academy of Dermatology

33. Ultrastructural Analysis of the Foreskin in Patients with True Phimosis Treated or Not- Treated with Topic Betamethasone and Hyaluronidase Ointment. (PubMed)

Ultrastructural Analysis of the Foreskin in Patients with True Phimosis Treated or Not- Treated with Topic Betamethasone and Hyaluronidase Ointment. To evaluate, by using scanning electron microscopy (SEM), the possible alterations of the foreskin connective tissue in patients with true phimosis submitted to topical treatment with betamethasone and hyaluronidase ointment.We studied 15 patients (mean 5.3 years old) submitted or not to topical application of betamethasone 0.2% and hyaluronidase (...) not agree with the clinical treatment and opted for circumcision directly. These patients served as the control group (nontreated). Eight patients submitted to topical treatment could not expose the glans and were referred for circumcision. In SEM, with a magnification of 5000×, we observed important differences in the organization of the collagen and elastic system fibers when comparing treated and nontreated patients with betamethasone and hyaluronidase. Treated patients presented a different

2016 Urology

34. Comparison of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic® Ointment 0.1% in Treating Atopic Dermatitis

by itchiness. Topical corticosteroids are typically used to treat AD. However, many patients have concerns about the safety of long-term use, and seek alternative therapies such as traditional Chinese medicine (TCM). In TCM, indigo naturalis has been used to treat various infectious and inflammatory skin diseases for hundreds of years. The investigate also found that the results of indigo naturalis ointment treatment in other trial were comparable to the results of calcineurin inhibitor (such as Tacrolimus (...) of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic® (Tacrolimus 0.1%) Ointment in Treating Atopic Dermatitis: A Randomized, Evaluator-blind, Crossover, Active-Controlled Trial Estimated Study Start Date : April 1, 2019 Estimated Primary Completion Date : July 31, 2021 Estimated Study Completion Date : July 31, 2021 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental

2018 Clinical Trials

35. Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements

applied to sensitive skin locations on left side of body Drug: Within-Subject Active vs Placebo Topical Applications Crisaborole 2% ointment (right side) and Placebo vehicle ointment (left side) Group B (Crisaborole LEFT SIDE / Vehicle RIGHT SIDE) Crisaborole placebo vehicle ointment applied to 7 sensitive skin sites on right side of body. Crisaborole ointment 2% applied to 7 sensitive skin locations on left side of body Drug: Within-Subject Active vs. Placebo Topical Applications Crisaborole 2 (...) Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search

2018 Clinical Trials

36. Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment

Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment Chronic anal fissure: 0.2% topical gly Chronic anal fissure: 0.2% topical glyceryl ceryl trinitr trinitrate ointment ate ointment Evidence summary Published: 26 March 2013 nice.org.uk/guidance/esuom7 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in March 2013. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF (...) . It is not known whether applying less ointment of the same strength, rather than reducing the strength of ointment applied, might have an effect on the incidence or headache. The evidence for unlicensed 2% topical diltiazem hydrochloride is discussed in detail in the evidence summary Chronic anal fissure: 2% topical diltiazem hydrochloride. About this e About this evidence summary vidence summary 'Evidence summaries: unlicensed or off-label medicines' summarise the published evidence for selected unlicensed

2013 National Institute for Health and Clinical Excellence - Advice

37. Are Topical Nonsteroidal Anti-Inflammatory Drugs Useful for Analgesia in Patients With Traumatic Corneal Abrasions?

, the frequency of healing at 24 and 48 hours after injury, whether the use of concurrent topical antibiotics (drops or ointments) with additional lubricating effects reduced pain, and the complications of corneal abrasions through the use of topical nonsteroidal anti-inflammatory drugs versus the control groups. Data Extraction and Synthesis Two reviewers independently assessed the articles for eligibility, performed data extraction, assessed risk of bias by the Cochrane Risk of Bias Tool, x 1 Higgins, J.P (...) ointment versus topical polyvinyl alcohol and an ophthalmic antibiotic ointment, x 9 Brahma, A.K., Shah, S., Hillier, V.F. et al. Topical analgesia for superficial corneal injuries. J Accid Emerg Med . 1996 ; 13 : 186–188 | | a topical nonsteroidal anti-inflammatory drug versus topical polyvinyl alcohol, x 10 Goyal, R., Shankar, J., Fone, D.L. et al. Randomised controlled trial of ketorolac in the management of corneal abrasions. Acta Ophthalmol Scand . 2001 ; 79 : 177–179 | | | and a topical

2019 Annals of Emergency Medicine Systematic Review Snapshots

38. Contact Dermatitis after Prescription of an Ophthalmic Ointment Containing Fradiomycin Sulfate: A Retrospective Database Study Using Japanese Health Insurance Claims Data (PubMed)

Contact Dermatitis after Prescription of an Ophthalmic Ointment Containing Fradiomycin Sulfate: A Retrospective Database Study Using Japanese Health Insurance Claims Data Topical ointments containing fradiomycin sulfate, such as fradiomycin sulfate/methylprednisolone (F/M) and fradiomycin sulfate/betamethasone sodium phosphate (F/B), are known to cause allergic contact dermatitis (CD) in some patients, especially when used for the periocular region. F/M is commonly prescribed to patients (...) that there was no clear difference in the incidence of CD after filling prescriptions for F/M, F/B, and ophthalmic ointment containing a steroid, while the incidence with antibiotics was lower by 0.03-0.04 compared with the other groups. Considering the observation that the investigational drugs were repeatedly prescribed even after the diagnosis of CD, it is critical that the risk of CD with these prescribed topical ointments is better understood by primary care physicians in order to take appropriate

Full Text available with Trip Pro

2017 Drugs - real world outcomes

39. Vitamin D ointment for prevention of radiation dermatitis in breast cancer patients (PubMed)

day, after the delivery of radiation. Skin reaction was recorded and compared between the two halves of the breast. Vitamin D was well tolerated by patients with no local or systemic allergic reactions. Radiation dermatitis was not significantly different between both treatment arms. Topical vitamin D ointment is not superior to Aqua cream for prevention of radiation-induced dermatitis in women treated with adjuvant radiation for breast cancer. (...) Vitamin D ointment for prevention of radiation dermatitis in breast cancer patients Radiation dermatitis occurs frequently during adjuvant radiation therapy for breast cancer. Prevention of radiation dermatitis by applying various creams and ointments has a limited success, and Aqua cream which has urea as one of its active ingredients is used in many institutions as a preventive treatment. The primary goal of this study is to assess the effect of vitamin D (calcipotriol) ointment in prevention

Full Text available with Trip Pro

2017 NPJ breast cancer

40. Topical antimicrobial agents for treating foot ulcers in people with diabetes. (PubMed)

also searched clinical trials registries for ongoing and unpublished studies, and checked reference lists to identify additional studies. We used no restrictions with respect to language, date of publication, or study setting.We included randomised controlled trials conducted in any setting (inpatient or outpatient) that evaluated topical treatment with any type of solid or liquid (e.g., cream, gel, ointment) antimicrobial agent, including antiseptics, antibiotics, and antimicrobial dressings (...) Topical antimicrobial agents for treating foot ulcers in people with diabetes. People with diabetes are at high risk for developing foot ulcers, which often become infected. These wounds, especially when infected, cause substantial morbidity. Wound treatments should aim to alleviate symptoms, promote healing, and avoid adverse outcomes, especially lower extremity amputation. Topical antimicrobial therapy has been used on diabetic foot ulcers, either as a treatment for clinically infected wounds

Full Text available with Trip Pro

2017 Cochrane

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>